[1]
S. Todorović, “RISK OF COVID-19 INFECTION IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH OCRELIZUMAB – A SINGLE CENTER EXPERIENCE”, АММ, vol. 62, no. 3, Nov. 2023, Accessed: Nov. 18, 2026. Available: https://test.aseestant.ceon.rs/index.php/amm/article/view/41552